Jun 01, 2016 7:00am EDT Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis
May 27, 2016 7:00am EDT Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update
May 02, 2016 7:00am EDT Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association's Annual Meeting
Apr 29, 2016 7:00am EDT Can-Fite to Present at Joseph Gunnar & Co.'s Pioneers 2016 Conference in New York City on May 5, 2016
Apr 11, 2016 7:00am EDT Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose
Apr 04, 2016 7:00am EDT Can-Fite to Participate in BIO-Europe Partnering Conference on April 4-6, 2016 in Stockholm, Sweden
Mar 17, 2016 7:00am EDT Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis
Mar 03, 2016 7:00am EST Can-Fite to Present Psoriasis Data at American Academy of Dermatology's 74th Annual Meeting in Washington D.C. on March 7, 2016
Feb 05, 2016 7:00am EST Can-Fite to Present at BIO CEO & Investor Conference in New York City on February 8, 2016
